Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer

Gynecologic Oncology
M Rodriguez, P G Rose

Abstract

Topotecan (1.5 mg/m(2)) administered daily for 5 consecutive days of a 21-day cycle is an established chemotherapeutic regimen in recurrent ovarian cancer. However, noncumulative myelosuppression has limited its use by many clinicians. We sought to determine whether a lower dose of topotecan could provide comparable tumor activity and higher tolerability in pretreated ovarian cancer patients. A retrospective chart review was conducted on recurrent ovarian, peritoneal, or fallopian tube cancer patients with measurable disease or elevated cancer antigen 125 levels (evaluable disease). Patients were treated with topotecan (1.0 mg/m(2)) given by 30-min intravenous infusion for 5 consecutive days every 21 days until disease progression or unacceptable toxicity. Treatment records from 37 women who had been treated with a median of 3 courses (range, 1 to 17) of lower dose topotecan were evaluated; all were evaluable for tolerability and 36 were evaluable for response. Patients had received a median of 3 (range, 1 to 6) previous treatments. The overall response rate was 22% (8/36); the response rates for patients with evaluable disease and measurable disease were 35.7 (5/14) and 13.6% (3/22), respectively. An additional 8 patients (22%...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Dec 2, 1992·Journal of the National Cancer Institute·H A BurrisD D Von Hoff
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireJ Woodward
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Sep 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VerweijH Hansen
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinH E Lambert
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P KudelkaJ J Kavanagh
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S O'ReillyL B Grochow
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Sep 23, 1997·Gynecologic Oncology·E M SwisherT J Herzog
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P HoskinsB Zee
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireC J Dunton
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun

❮ Previous
Next ❯

Citations

Sep 22, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S K MitchellL S Downs
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K F TamH Y S Ngan
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F VecchioneA A Lissoni
Jan 13, 2010·Journal of Oncology·Kimio Ushijima
Jul 25, 2014·Japanese Journal of Clinical Oncology·Masahiro MoriseYuichiro Ohe
Feb 15, 2003·Gynecologic Oncology·John V BrownJohn Paul Micha
Feb 13, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·I VandenputI Vergote
Aug 5, 2003·Current Oncology Reports·Maurie Markman
Oct 17, 2006·Current Oncology Reports·Thomas J Herzog
May 13, 2008·Expert Review of Anticancer Therapy·Stephanie L WethingtonThomas J Herzog
Sep 22, 2009·Critical Reviews in Oncology/hematology·Domenica LorussoGiovanni Scambia
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Tanya Ahmad, Martin Gore
Nov 5, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·Nelson Gustavo Neder Kalil, William Patrick McGuire
Jul 15, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B Piura, A Rabinovich
Feb 3, 2004·The Oncologist·Eric T Wong, Anna Berkenblit
Jun 5, 2004·The Oncologist·Emily Bergsland, Maura N Dickler
Nov 15, 2014·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Samantha RussellJim Petrik
Mar 7, 2014·International Journal of Molecular Sciences·Mike-Andrew WesthoffKlaus-Michael Debatin
Sep 27, 2002·The Oncologist·Charles J Dunton
Aug 23, 2002·Current Opinion in Oncology·Emery SalomRamin Mirhashemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.